EnteroBiotix
Develops full-spectrum microbiome therapeutics for gastrointestinal diseases including IBS
£19MSeries B
Role not disclosedLoading investors…
Activity from announced rounds
Develops full-spectrum microbiome therapeutics for gastrointestinal diseases including IBS